Novartis' SOLAR-1 Study Shines on Alpelisib In Breast Cancer
The selective PI3K inhibitor, alpelisib, met its primary PFS endpoint in top-line data from the SOLAR-1 study, but further details are needed from the trial in order to judge the drug's likely penetration of the HR-positive, HER2-negative breast cancer population.
You may also be interested in...
It has taken a while but European regulators have finally followed their US counterparts and approved Piqray, making it the first targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation.
Big pharma and little biotechs are getting ready to pack their bags for Germany where over 2,000 abstracts will be presented at ESMO and the fine details on some major oncology studies will be closely watched.
Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.